Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.
Ontology highlight
ABSTRACT: Multiple sclerosis treatment made substantial headway during the last two decades with the implementation of therapeutics with new modes of action and routes of application. We are now in the situation that second-generation molecules, approved since 2018, are on the market, characterized by reduced side effects using a more tailored therapeutic approach. Diroximel fumarate is a second-generation fumarate with reduced gastrointestinal side effects. Moreover, several novel, selective, sphingosine-1-phosphate receptor modulators with reduced off-target effects have been developed; namely siponimod, ozanimod, and ponesimod; all oral formulations. B-cell-targeted therapies such as ocrelizumab, given intravenously, and since 2021 ofatumumab, applied subcutaneously, complement the spectrum of no
SUBMITTER: Faissner S
PROVIDER: S-EPMC9307218 | biostudies-literature | 2022 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA